NCT01149057View on ClinicalTrials.gov

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS

PHASE4CompletedINTERVENTIONAL

Enrollment

145

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions

Rheumatoid Arthritis

Interventions

DRUG

tocilizumab [RoActemra/Actemra]

8 mg/kg intravenously, every 4 weeks for 96 weeks

Trial Locations (16)

18101

Afula

34362

Haifa

38100

Hadera

44281

Kfar Saba

58100

Holon

76100

Rehovot

78306

Ashkelon

91240

Jerusalem

3109601

Haifa

3339419

Haifa

4941492

Petah Tikva

5262000

Ramat Gan

6093000

Beer Yaakov

6423906

Tel Aviv

8410101

Beersheba

9112001

Jerusalem

Sponsors

Collaborators (1)

Clalit Health Services

All Listed Sponsors

collaborator

Clalit Health Services

OTHER

lead

Hoffmann-La Roche

INDUSTRY